1h Free Analyst Time
The tardive dyskinesia treatment market is forecasted to grow by USD 632.45 mn during 2023-2028, accelerating at a CAGR of 4.73% during the forecast period. The report on the tardive dyskinesia treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of mental disorders, growing antipsychotic prescription, and huge unmet need for neurological disease treatments.
The tardive dyskinesia treatment market is segmented as below:
By End-user
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Product
- Austedo and lngrezza
- Amantadine
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the tardive dyskinesia treatment market covers the following areas:
- Tardive dyskinesia treatment market sizing
- Tardive dyskinesia treatment market forecast
- Tardive dyskinesia treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global tardive dyskinesia treatment market: Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is initiatives to spread awareness regarding treatment of tardive dyskinesia.'
According to the report, one of the major drivers for this market is the rising cases of mental disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Actiza Pharmaceutical Pvt. Ltd.
- Alembic Pharmaceuticals Ltd.
- Aspire Pharma Ltd.
- Centaur Pharmaceuticals Pvt. Ltd.
- Cipla Ltd.
- Hetero Labs Ltd.
- Lannett Co. Inc.
- Luye Pharma Group Ltd.
- Neurocrine Biosciences Inc.
- Novartis AG
- Psicofarma S. A. de C. V
- Ryon pharma
- Sawai Group Holdings Co. Ltd.
- Slate Run Pharmaceuticals LLC
- Solco Healthcare
- SOM Innovation Biotech S.A.
- SteriMax Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.